Teprotumumab
E854987
Teprotumumab is a monoclonal antibody drug used primarily to treat thyroid eye disease by targeting the insulin-like growth factor-1 receptor (IGF-1R).
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
IGF-1R inhibitor
ⓘ
monoclonal antibody ⓘ |
| hasAbbreviation | IGF-1R NERFINISHED ⓘ |
| hasAdministrationSetting | infusion center ⓘ |
| hasAntibodyType | IgG1 ⓘ |
| hasApprovalRegion | United States NERFINISHED ⓘ |
| hasApprovalYear | 2020 ⓘ |
| hasATCCode | L01FX15 ⓘ |
| hasBlackBoxWarning | false ⓘ |
| hasClinicalTrialPhaseAtApproval | Phase 3 ⓘ |
| hasCommonAdverseEffect |
alopecia
ⓘ
diarrhea ⓘ fatigue ⓘ hearing impairment ⓘ hyperglycemia ⓘ muscle spasm ⓘ nausea ⓘ |
| hasContraindication | pregnancy ⓘ |
| hasDeveloper | Horizon Therapeutics NERFINISHED ⓘ |
| hasDosingRegimen | intravenous infusion every 3 weeks for 8 doses ⓘ |
| hasEffect |
improves clinical activity score in thyroid eye disease
ⓘ
improves diplopia ⓘ reduces proptosis ⓘ |
| hasIndication |
Graves orbitopathy
NERFINISHED
ⓘ
active thyroid eye disease ⓘ thyroid eye disease ⓘ thyroid-associated ophthalmopathy NERFINISHED ⓘ |
| hasInitialDose | 10 mg/kg ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMechanismOfAction |
blocks IGF-1R signaling
ⓘ
inhibits IGF-1R autoantibody activation ⓘ reduces orbital fibroblast activation ⓘ reduces orbital inflammation ⓘ reduces tissue expansion behind the eye ⓘ |
| hasMolecularType | human monoclonal antibody ⓘ |
| hasRegulatoryApproval | FDA NERFINISHED ⓘ |
| hasRouteOfAdministration | intravenous infusion ⓘ |
| hasSubsequentDose | 20 mg/kg ⓘ |
| hasTarget | insulin-like growth factor-1 receptor NERFINISHED ⓘ |
| hasTargetSpecies | human ⓘ |
| hasTherapeuticArea |
endocrinology
ⓘ
ophthalmology ⓘ |
| hasTradeName | Tepezza NERFINISHED ⓘ |
| hasWarning |
may cause infusion reactions
ⓘ
may worsen glycemic control in diabetic patients ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isFirstInClass | true ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.